Positive Results for TYSABRI
Two-year data from the AFFIRM Phase III monotherapy trial presented for the first time, showed that treatment with TYSBARI (natalizumab)…
network
Two-year data from the AFFIRM Phase III monotherapy trial presented for the first time, showed that treatment with TYSBARI (natalizumab)…